Martin Schuler, Jörg Hense, Kaid Darwiche, Sebastian Michels, Hubertus Hautzel, Carsten Kobe, Smiths Lueong, Martin Metzenmacher, Thomas Herold, Gregor Zaun, Katharina Laue, Alexander Drzezga, Dirk Theegarten, Felix Nensa, Jürgen Wolf, Ken Herrmann, Marcel Wiesweg
Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has established the precision oncology paradigm in lung cancer. Most patients with EGFR -mutated lung cancer respond but eventually acquire resistance. Methods: Patients exhibiting the EGFR p.T790M resistance biomarker benefit from sequenced targeted therapy with osimertinib. We hypothesized that metabolic response as detected by 18 F-FDG PET after short-course osimertinib identifies additional patients susceptible to sequenced therapy...
April 4, 2024: Journal of Nuclear Medicine